Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELIAS J JABBOUR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215108303
CMS profile
145451
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120,282.65

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $27,122.42 20
PFIZER INC. $25,806.78 28
Hikma Pharmaceuticals USA $19,029.00 5
Incyte Corporation $12,828.41 7
Kite Pharma, Inc. $10,447.22 9
E.R. Squibb & Sons, L.L.C. $9,239.42 20
Daiichi Sankyo Inc. $4,793.77 6
Novartis Pharmaceuticals Corporation $4,125.00 1
AbbVie, Inc. $3,250.00 1
Adaptive Biotechnologies Corporation $3,229.94 3
Genentech USA, Inc. $211.42 4
Astellas Pharma US Inc $174.31 2
Merck Sharp & Dohme Corporation $13.26 1
GlaxoSmithKline, LLC. $11.70 1

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELIAS J JABBOUR

NPI 1215108303 · CMS profile ID 145451

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $120,282.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $372.7802/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651290033 CMS
E.R. Squibb & Sons, L.L.C. $88.4402/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651290035 CMS
E.R. Squibb & Sons, L.L.C. $159.8802/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651290053 CMS
E.R. Squibb & Sons, L.L.C. $55.0002/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651290055 CMS
E.R. Squibb & Sons, L.L.C. $111.0701/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651289969 CMS
PFIZER INC. $780.0001/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673795623 CMS
PFIZER INC. $780.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673794857 CMS
PFIZER INC. $3,200.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673795297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120,282.65 108
PY2020 $83,331.48 31
PY2021 $154,771.29 56
PY2022 $187,529.50 75
PY2023 $286,346.08 109
PY2024 $231,008.56 147
PY2025 $198,442.88 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,006.59 7
PY2025 Principal investigator $73,248,563.28 50
PY2024 Recipient $9,386.00 3
PY2024 Principal investigator $35,345,738.74 69
PY2023 Recipient $6,000.00 3
PY2023 Principal investigator $34,282,742.92 57
PY2022 Recipient $330.00 1
PY2022 Principal investigator $41,750,052.06 64
PY2021 Recipient $1,524.53 3
PY2021 Principal investigator $38,675,338.28 51
PY2020 Recipient $21,090.58 7
PY2020 Principal investigator $23,293,883.37 60
PY2019 Recipient $149.67 1
PY2019 Principal investigator $16,200,987.04 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $208,546.66 12/16/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB No dispute reported 06/30/2026 1223273051
Principal investigator 1 Novartis Pharmaceuticals Corporation $434,274.00 12/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Open/label phase II study of asciminib as second line therapy for adult patients with CML/CP post frontline TKI failure No dispute reported 06/30/2026 1190309304
Recipient Novartis Pharmaceuticals Corporation $786.00 12/08/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291481
Principal investigator 1 PFIZER INC. $458,160.00 12/08/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB No dispute reported 06/30/2026 1228740011
Principal investigator 1 PFIZER INC. $458,160.00 12/08/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA No dispute reported 06/30/2026 1228747230
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,628,527.50 12/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) No dispute reported 06/30/2026 1190309302
Principal investigator 1 Janssen Research & Development, LLC $2,869.90 11/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175402972
Principal investigator 1 Janssen Research & Development, LLC $832.00 10/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175403292
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,830,000.00 10/21/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223273041
Principal investigator 1 Janssen Research & Development, LLC $72,470.00 10/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy No dispute reported 06/30/2026 1175403024
Principal investigator 1 Amgen Inc. $69.37 10/08/2025 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL No dispute reported 06/30/2026 1246644041
Principal investigator 1 Janssen Research & Development, LLC $2,869.90 10/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403663
Principal investigator 1 Adaptive Biotechnologies Corporation $4,950.00 10/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
2010-0991 No dispute reported 06/30/2026 1254908893
Principal investigator 1 PFIZER INC. $458,160.00 09/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB No dispute reported 06/30/2026 1228747915
Principal investigator 1 Amgen Inc. $1,834,203.60 09/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL) No dispute reported 06/30/2026 1246638190
Principal investigator 1 ABBVIE INC. $2,081.60 09/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1202431641
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,212,640.00 08/28/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF COMBINATION OF HYPER-CVAD AND PONATINIB IN PATIENTS WITH PHILADELPHIA (PH) CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223273031
Principal investigator 1 Janssen Research & Development, LLC $2,869.90 08/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403486
Recipient Novartis Pharmaceuticals Corporation $324.09 08/05/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293501
Principal investigator 1 Autolus Inc $4,938.00 07/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
AUTO1-AL1 No dispute reported 06/30/2026 1243667764
Principal investigator 1 Autolus Inc $3,750.00 07/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
AUTO1-AL1 No dispute reported 06/30/2026 1243667766
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,363,600.00 07/24/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223273013
Principal investigator 1 PFIZER INC. $939,228.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB No dispute reported 06/30/2026 1228740105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,332,000.00 07/02/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CCR-MDACC-PON-002: PHASE II STUDY OF THE SEQUENTIAL COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223273009
Principal investigator 1 PFIZER INC. $687,240.00 06/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA No dispute reported 06/30/2026 1228754475
Recipient PFIZER INC. $940.00 06/15/2025 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770292
Principal investigator 1 Janssen Research & Development, LLC $2,869.90 06/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403124
Recipient PFIZER INC. $940.00 06/01/2025 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760985
Principal investigator 1 PFIZER INC. $343,620.00 05/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB No dispute reported 06/30/2026 1228751865
Recipient Novartis Pharmaceuticals Corporation $356.50 05/15/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293505
Principal investigator 1 Novartis Pharmaceuticals Corporation $511,050.00 05/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) No dispute reported 06/30/2026 1190294280
Principal investigator 1 Janssen Research & Development, LLC $5,739.80 05/05/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175402940
Principal investigator 1 Janssen Research & Development, LLC $47,514.00 05/05/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175403727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,490,400.00 04/28/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB No dispute reported 06/30/2026 1223272989
Principal investigator 1 Amgen Inc. $6,863,792.80 04/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab with or without Inotuzumab Ozogamicin as Frontline Therapy for Adults with B-Cell Lineage Acute Lymphocytic Leukemia No dispute reported 06/30/2026 1246638194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,418,640.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223272985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,109,360.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223272987
Principal investigator 1 PFIZER INC. $366,528.00 04/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA No dispute reported 06/30/2026 1228753784
Principal investigator 1 Amgen Inc. $3,668,932.80 04/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) No dispute reported 06/30/2026 1246638192
Principal investigator 1 Janssen Research & Development, LLC $12,694.00 04/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175403419
Principal investigator 1 Amgen Inc. $2,500.00 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) No dispute reported 06/30/2026 1246638188
Principal investigator 1 Janssen Research & Development, LLC $2,869.90 03/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175402873
Principal investigator 1 ABBVIE INC. $166,095.28 03/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA No dispute reported 06/30/2026 1202430226
Principal investigator 1 Janssen Research & Development, LLC $9,641.00 03/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175403712
Recipient PFIZER INC. $330.00 02/28/2025 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768482
Recipient PFIZER INC. $330.00 02/28/2025 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768539
Principal investigator 1 ABBVIE INC. $12,780.40 02/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA No dispute reported 06/30/2026 1202430076
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,582,760.50 02/10/2025 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS
Open/label phase II study of asciminib as second line therapy for adult patients with CML/CP post frontline TKI failure No dispute reported 06/30/2026 1190306657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,584,800.00 02/06/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF COMBINATION OF HYPER-CVAD AND PONATINIB IN PATIENTS WITH PHILADELPHIA (PH) CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223272965
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,811,200.00 01/30/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB No dispute reported 06/30/2026 1223272961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,811,200.00 01/30/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB No dispute reported 06/30/2026 1223272963
Principal investigator 1 ABBVIE INC. $398,259.00 01/28/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A16-219;Venclexta;Bottle: ABT-263 100mg Film Coated Tablet 60 Tablets No dispute reported 06/30/2026 1202429845
Principal investigator 1 PFIZER INC. $343,620.00 01/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA No dispute reported 06/30/2026 1228751537
Principal investigator 1 Amgen Inc. $5,783,014.97 01/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL No dispute reported 06/30/2026 1246638142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,528,000.00 01/09/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) No dispute reported 06/30/2026 1223272955
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,268,240.50 01/06/2025 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS
Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) No dispute reported 06/30/2026 1190306655
Principal investigator 1 PFIZER INC. $160,000.00 01/06/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA No dispute reported 06/30/2026 1228800960